Read the rest of this entry »

Click here to see the details and full-size versions of this ad on AdPharm

AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.

A pioneer in cancer innovation – exploring new directions

At Genentech BioOncology, we're leading the fight against cancer with innovative science and are working to transform cancer treatment.

A family of Firsts
A robust pipeline
A commitment to patients.

www.biooncology.com

Generic name/category: Bio oncology
Company: Genentech
Country/Market: USA, North America
Indication(s)/use: Corporate awareness
Target: Healthcare Professionals (HCP)
Tagline: Translating science into life
Medium: Print ad
Size/duration: double-page spread
Publication/Aired: Blood – August 20, 2009
1 views
Sep 17, 2009

Visit AdPharm.net for more pharmaceutical ads

Take IV iron therapy to a proven place:
Response with toleration!

The only first-line IV iron for pre-dialysis CKD patients…

Venofer (iron sucrose injection) is a complex of polynuclear iron (III)-hydroxide in sucrose. It is approved for use in replenishing iron in patients receiving erythropoietin (a hormone that stimulates red blood cell production) and undergoing chronic hemodialysis, which involves filtering the blood in order to remove waste products. In these patients, an iron deficiency is caused by blood loss during the dialysis procedure, increased erythropoiesis (red blood cell production), and insufficient absorption of iron from the gastrointestinal tract. Iron is essential for the synthesis of hemoglobin, which is responsible for the transport of oxygen throughout the body.

More on Medilexicon

Brand name: Venofer
Generic name/category: iron sucrose injection
Company: American Regent
Country/Market: USA, North America
Indication(s)/use: replenishing iron in patients receiving erythropoietin (a hormone that stimulates red blood cell production) and undergoing chronic hemodialysis
Target: Healthcare Professionals (HCP)
Tagline: Reinvigorating anemia management.
Medium: Print ad
Size/duration: double-page spread
Publication/Aired: Blood – August 13, 2009
1 views
Sep 17, 2009

Visit AdPharm.net for more pharmaceutical ads

Rise above resistance

Trisenox uses a targeted, multifunctional approach to deliver high rates of remission with minimal chemotherapy-related side effects.

Trisenox (arsenic trioxide), injectable formulation, is indicated for the treatment of induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.

More on Medilexicon

Brand name: Trisenox
Generic name/category: arsenic trioxide, IARC Group 1 carcinogens, Antineoplastic drugs
Company: Cephalon Oncology
Country/Market: USA, North America
Indication(s)/use: acute promyelocytic leukemia (APL)
Target: Healthcare Professionals (HCP)
Tagline: Rise above resistance
Medium: Print ad
Size/duration: single-page
Publication/Aired: Blood – September 10, 2009
1 views
Sep 17, 2009

Visit AdPharm.net for more pharmaceutical ads

For patients with life-threatening fungal infections
There's no time for a second chance

Voriconazole (VFEND, Pfizer) is a triazole antifungal medication that is generally used to treat serious, invasive fungal infections. These are generally seen in patients who are immunocompromised, and include invasive candidiasis, invasive aspergillosis, and certain emerging fungal infections.

More on Wikipedia

Brand name: Vfend
Generic name/category: Voriconazole, Antifungals, Triazoles
Company: Pfizer
Country/Market: USA, North America
Indication(s)/use: invasive fungal infections, candidiasis, aspergillosis, and certain emerging fungal infections.
Target: Healthcare Professionals (HCP)
Tagline: When it matters most
Medium: Print ad
Size/duration: single-page
Publication/Aired: Blood – August 20, 2009

To see all of this brand's ads on AdPharm, click here
1 views
Sep 17, 2009

Visit AdPharm.net for more pharmaceutical ads

In a typical hemolytic uremic syndrome (aHUS)
Unregulated complement.
Unimaginable destruction.

Now recruiting patients for the first ever complement inhibitor trials for aHUS.

In medicine, hemolytic-uremic syndrome (or haemolytic-uraemic syndrome, abbreviated HUS) is a disease characterized by hemolytic anemia, acute renal failure (uremia) and a low platelet count (thrombocytopenia). It predominantly but not exclusively affects children. Most cases are preceded by an episode of diarrhea caused by E. coli O157:H7, which is acquired as a foodborne illness. It is a medical emergency and carries a 5???10% mortality; of the remainder, the majority recover without major consequences but a small proportion develop chronic kidney disease and become reliant on renal replacement therapy.

HUS was first defined as a syndrome in 1955.

More on Wikipedia

Generic name/category: Clinical trials
Company: Alexion Pharmaceuticals
Country/Market: USA, North America
Indication(s)/use: Atypical hemolytic uremic syndrome
Target: Healthcare Professionals (HCP)
Tagline: Innovators in complement inhibition
Medium: Print ad
Size/duration: single-page
Publication/Aired: Blood – August 13, 2009

To see all of this brand's ads on AdPharm, click here
0 views
Sep 17, 2009

Visit AdPharm.net for more pharmaceutical ads